José Júlio Costa Sidrim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
José Júlio Costa Sidrim has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Débora de Souza Collares Maia Castelo-Branco
Federal University of Ceará
19 shared publications - Marcos Fábio Gadelha Rocha
Federal University of Ceará
19 shared publications - Rossana de Aguiar Cordeiro
Department of Pathology and Legal Medicine, Federal University of Ceará
18 shared publications Marcos Fábio Gadelha Rocha
Department of Pathology & Legal Medicine, Postgraduate Program in Medical Microbiology, Specialized Medical Mycology Center, Federal University of Ceará , Rua Coronel, Nunes de Melo, 1315 - Rodolfo Teófilo - CEP 60430-275, Fortaleza, Ceará , Brazil
13 shared publications- Raimunda Sâmia Nogueira Brilhante
Department of Pathology and Legal Medicine, School of Medicine, One Health Microbiology Laboratory, Postgraduate Program in Medical Sciences, Federal University of Ceará
11 shared publications Raimunda Sâmia Nogueira Brilhante
Specialized Medical Mycology Center, Postgraduate Program in Medical Microbiology, Department of Pathology and Legal Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil
8 shared publications
Latest Publications
- 13 June 2026
- Published by Taylor & Francis in Future Microbiology
- Vol. 21 (9) , 913-928
Applications of lupeol to manage fungal infections: a promising multi-target molecule
Lupeol, a pentacyclic triterpene found in various plant species, has gained prominence due to its antioxidant, anticancer, anti-inflammatory, antifungal properties, along with its low toxicity. In view of the increasing resistance to antifungal agents and the limited therapeutic arsenal available, research on natural bioactive compounds with antimicrobial potential, such as lupeol, has intensified. This review compiles and critically discusses evidence identified through a literature search performed in SciELO, PubMed, Scopus, Web of Science, ScienceDirect, and additional relevant sources for studies published from 2003 to 2025, using combined descriptors related to lupeol, antifungal activity, fungal infections, Candida, Cryptococcus, Aspergillus, dermatophytes, biofilm, virulence factors, mechanisms of action, pharmacokinetics, bioavailability, nanoformulations, nanotechnology, molecular docking, molecular dynamics, and in silico approaches. The pharmacokinetic properties of lupeol and the nanotechnological strategies aimed at enhancing its biopharmaceutical potential are also discussed. In addition, in silico approaches that have contributed to understanding the molecular interactions of lupeol with fungal targets are presented, as well as the development of new derivatives. In summary, this article identifies lupeol as a promising multifunctional molecule for antifungal therapy in the face of increasing microbial resistance and the demand for more effective and less harmful antifungal agents.
- 13 June 2026
- Published by Taylor & Francis in Future Microbiology
- Vol. 21 (9) , 913-928
Applications of lupeol to manage fungal infections: a promising multi-target molecule
Lupeol, a pentacyclic triterpene found in various plant species, has gained prominence due to its antioxidant, anticancer, anti-inflammatory, antifungal properties, along with its low toxicity. In view of the increasing resistance to antifungal agents and the limited therapeutic arsenal available, research on natural bioactive compounds with antimicrobial potential, such as lupeol, has intensified. This review compiles and critically discusses evidence identified through a literature search performed in SciELO, PubMed, Scopus, Web of Science, ScienceDirect, and additional relevant sources for studies published from 2003 to 2025, using combined descriptors related to lupeol, antifungal activity, fungal infections, Candida, Cryptococcus, Aspergillus, dermatophytes, biofilm, virulence factors, mechanisms of action, pharmacokinetics, bioavailability, nanoformulations, nanotechnology, molecular docking, molecular dynamics, and in silico approaches. The pharmacokinetic properties of lupeol and the nanotechnological strategies aimed at enhancing its biopharmaceutical potential are also discussed. In addition, in silico approaches that have contributed to understanding the molecular interactions of lupeol with fungal targets are presented, as well as the development of new derivatives. In summary, this article identifies lupeol as a promising multifunctional molecule for antifungal therapy in the face of increasing microbial resistance and the demand for more effective and less harmful antifungal agents.
- Open Access
- 4 July 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (7) , 640
Levamisole as a Strategy Against Bacteria from Canine Otitis Externa: An In Vitro Evaluation
Canine otitis externa is a prevalent condition, and inadequate treatment may favor the emergence of multidrug-resistant microorganisms. Drug repurposing provides an alternative approach for the management of this disease. Thus, this study aimed at assessing the antimicrobial and antibiofilm properties of levamisole against bacterial strains recovered from dogs with otitis externa as well as its influence on biofilm growth dynamics during 120 h. A total of 50 clinical bacterial isolates were subjected to analysis. Planktonic bacterial susceptibility to levamisole was assessed by broth microdilution to determine the minimum inhibitory concentration (MIC), the lowest concentration that completely inhibits bacterial growth. The activity against mature biofilms was assessed by determining the minimum biofilm eradication concentration (MBEC). The effect of levamisole on biofilm formation was evaluated at the MIC and at two subinhibitory concentrations, with daily readings recorded at 48, 72, 96, and 120 h. MICs of levamisole ranged from 0.58 to 2.34 mg/mL. Levamisole reduced the biomass of mature biofilms (p < 0.05), with MBEC values ranging from 1.17 to 18.75 mg/mL, and biofilm formation was significantly reduced at the MIC concentration (1.17 mg/mL) for all isolates for 120 h (p < 0.05). Levamisole demonstrated potential as a preventive approach against biofilm-associated bacterial otitis.
- 4 July 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (7) , 640
Open AccessLevamisole as a Strategy Against Bacteria from Canine Otitis Externa: An In Vitro Evaluation
Canine otitis externa is a prevalent condition, and inadequate treatment may favor the emergence of multidrug-resistant microorganisms. Drug repurposing provides an alternative approach for the management of this disease. Thus, this study aimed at assessing the antimicrobial and antibiofilm properties of levamisole against bacterial strains recovered from dogs with otitis externa as well as its influence on biofilm growth dynamics during 120 h. A total of 50 clinical bacterial isolates were subjected to analysis. Planktonic bacterial susceptibility to levamisole was assessed by broth microdilution to determine the minimum inhibitory concentration (MIC), the lowest concentration that completely inhibits bacterial growth. The activity against mature biofilms was assessed by determining the minimum biofilm eradication concentration (MBEC). The effect of levamisole on biofilm formation was evaluated at the MIC and at two subinhibitory concentrations, with daily readings recorded at 48, 72, 96, and 120 h. MICs of levamisole ranged from 0.58 to 2.34 mg/mL. Levamisole reduced the biomass of mature biofilms (p < 0.05), with MBEC values ranging from 1.17 to 18.75 mg/mL, and biofilm formation was significantly reduced at the MIC concentration (1.17 mg/mL) for all isolates for 120 h (p < 0.05). Levamisole demonstrated potential as a preventive approach against biofilm-associated bacterial otitis.
- Open Access
- 7 March 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (3) , 001976
Antimicrobial and antiparasitic potential of lupeol: antifungal effect on the Candida parapsilosis species complex and nematicidal activity against Caenorhabditis elegans
Introduction. There is growing concern about infections caused by non-albicans Candida species, including species of the Candida parapsilosis complex – which have seen a considerable increase in cases during the COVID-19 pandemic – in addition to concern about nematode resistance to currently used anthelmintics. Gap Statement. Lupeol is a triterpenoid phytosterol that has a wide range of biological activities, although its antifungal and antiparasitic potential is still poorly explored. Additionally, its effect on the biofilm of the C. parapsilosis species complex has not yet been studied. Aim. This study aimed to investigate the antifungal effect of lupeol against C. parapsilosis complex species, in planktonic cells and mature biofilms, as well as its nematicidal potential against Caenorhabditis elegans. In addition, molecular docking was performed to identify potential target molecules for lupeol’s antifungal effect. Methodology. Twelve strains of C. parapsilosis species complex were used. Planktonic susceptibility was performed through the broth microdilution assay, while the antibiofilm effect was investigated by measuring the biomass and metabolic activity. The antifungal mechanism of action of lupeol was investigated by target fishing. The evaluation of the nematicidal effect was performed using the C. elegans infection model. Results. Lupeol demonstrated antifungal activity against planktonic cells with a MIC between 64 and 512 µg ml−1. In mature biofilms, lupeol was able to reduce biomass starting from a concentration of 1024 µg ml−1 and reduce metabolic activity from a concentration of 64 µg ml−1. It was observed that there was interaction of lupeol with the enzyme 14α-demethylase. Furthermore, lupeol had a nematicidal effect from a concentration of 64 µg ml−1. Conclusion. Lupeol exhibits an antifungal effect on the C. parapsilosis species complex, in the planktonic and mature biofilm forms, possibly by affecting the ergosterol synthesis. Lupeol further demonstrated a nematicidal potential.
- 7 March 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (3) , 001976
Open AccessAntimicrobial and antiparasitic potential of lupeol: antifungal effect on the Candida parapsilosis species complex and nematicidal activity against Caenorhabditis elegans
Introduction. There is growing concern about infections caused by non-albicans Candida species, including species of the Candida parapsilosis complex – which have seen a considerable increase in cases during the COVID-19 pandemic – in addition to concern about nematode resistance to currently used anthelmintics. Gap Statement. Lupeol is a triterpenoid phytosterol that has a wide range of biological activities, although its antifungal and antiparasitic potential is still poorly explored. Additionally, its effect on the biofilm of the C. parapsilosis species complex has not yet been studied. Aim. This study aimed to investigate the antifungal effect of lupeol against C. parapsilosis complex species, in planktonic cells and mature biofilms, as well as its nematicidal potential against Caenorhabditis elegans. In addition, molecular docking was performed to identify potential target molecules for lupeol’s antifungal effect. Methodology. Twelve strains of C. parapsilosis species complex were used. Planktonic susceptibility was performed through the broth microdilution assay, while the antibiofilm effect was investigated by measuring the biomass and metabolic activity. The antifungal mechanism of action of lupeol was investigated by target fishing. The evaluation of the nematicidal effect was performed using the C. elegans infection model. Results. Lupeol demonstrated antifungal activity against planktonic cells with a MIC between 64 and 512 µg ml−1. In mature biofilms, lupeol was able to reduce biomass starting from a concentration of 1024 µg ml−1 and reduce metabolic activity from a concentration of 64 µg ml−1. It was observed that there was interaction of lupeol with the enzyme 14α-demethylase. Furthermore, lupeol had a nematicidal effect from a concentration of 64 µg ml−1. Conclusion. Lupeol exhibits an antifungal effect on the C. parapsilosis species complex, in the planktonic and mature biofilm forms, possibly by affecting the ergosterol synthesis. Lupeol further demonstrated a nematicidal potential.
- 12 April 2024
- Published by Taylor & Francis in Future Microbiology
- Vol. 19 (6) , 495-508
Repurposing approved drugs as potential efflux pump inhibitors in multidrug-resistant Pseudomonas aeruginosa
Aim: To evaluate the action of promethazine, fluoxetine and carbonyl cyanide 3-chlorophenylhydrazone as efflux pump inhibitors (EPIs) against multidrug-resistant Pseudomonas aeruginosa. Methods: Th...
- 12 April 2024
- Published by Taylor & Francis in Future Microbiology
- Vol. 19 (6) , 495-508
Repurposing approved drugs as potential efflux pump inhibitors in multidrug-resistant Pseudomonas aeruginosa
Aim: To evaluate the action of promethazine, fluoxetine and carbonyl cyanide 3-chlorophenylhydrazone as efflux pump inhibitors (EPIs) against multidrug-resistant Pseudomonas aeruginosa. Methods: Th...
- 3 October 2023
- Published by Oxford University Press (OUP) in Letters in Applied Microbiology
- Vol. 76 (10)
Antibiofilm activity of promethazine, deferiprone, and Manuka honey in an ex vivo wound model
This study evaluated the antibiofilm activity of promethazine, deferiprone and Manuka honey against Staphylococcus aureus and Pseudomonas aeruginosa in vitro and ex vivo in a wound model on porcine skin. The minimum inhibitory concentrations (MICs) and the effects of the compounds on biofilms were evaluated. Then, counting colony-forming units (CFUs) and confocal microscopy were performed on biofilms cultivated on porcine skin for evaluation of the compounds. For promethazine, MICs ranging from 97.66-781.25 µg/mL and minimum biofilm eradication concentration (MBEC) values ranging from 195.31-1562.5 µg/mL were found. In addition to reducing the biomass of both species’ biofilms. As for deferiprone, the MICs were 512 and >1024 µg/mL, the MBECs were ≥1024 µg/mL, and it reduced the biomass of biofilms. Manuka honey had MICs of 10-40%, MBECs of 20->40% and reduced the biomass of S. aureus biofilms only. Concerning the analyses in the ex vivo model, the compounds reduced (Pin vitro and ex vivo tests raises the possibility of using them against biofilm-associated wounds. However, further studies are needed to characterize the mechanisms of action and their effectiveness on biofilms in vivo.
- 3 October 2023
- Published by Oxford University Press (OUP) in Letters in Applied Microbiology
- Vol. 76 (10)
Antibiofilm activity of promethazine, deferiprone, and Manuka honey in an ex vivo wound model
This study evaluated the antibiofilm activity of promethazine, deferiprone and Manuka honey against Staphylococcus aureus and Pseudomonas aeruginosa in vitro and ex vivo in a wound model on porcine skin. The minimum inhibitory concentrations (MICs) and the effects of the compounds on biofilms were evaluated. Then, counting colony-forming units (CFUs) and confocal microscopy were performed on biofilms cultivated on porcine skin for evaluation of the compounds. For promethazine, MICs ranging from 97.66-781.25 µg/mL and minimum biofilm eradication concentration (MBEC) values ranging from 195.31-1562.5 µg/mL were found. In addition to reducing the biomass of both species’ biofilms. As for deferiprone, the MICs were 512 and >1024 µg/mL, the MBECs were ≥1024 µg/mL, and it reduced the biomass of biofilms. Manuka honey had MICs of 10-40%, MBECs of 20->40% and reduced the biomass of S. aureus biofilms only. Concerning the analyses in the ex vivo model, the compounds reduced (Pin vitro and ex vivo tests raises the possibility of using them against biofilm-associated wounds. However, further studies are needed to characterize the mechanisms of action and their effectiveness on biofilms in vivo.
- 25 August 2023
- Published by Taylor & Francis in Future Microbiology
- Vol. 18 (12) , 785-794
Effect of Fluoxetine On Planktonic and Biofilm Growth and the Antimicrobial Susceptibility of Burkholderia Pseudomallei
Aim: This study evaluated the effect of fluoxetine (FLU) on planktonic and biofilm growth and the antimicrobial susceptibility of Burkholderia pseudomallei. Materials & methods: The minimum inhibit...
- 25 August 2023
- Published by Taylor & Francis in Future Microbiology
- Vol. 18 (12) , 785-794
Effect of Fluoxetine On Planktonic and Biofilm Growth and the Antimicrobial Susceptibility of Burkholderia Pseudomallei
Aim: This study evaluated the effect of fluoxetine (FLU) on planktonic and biofilm growth and the antimicrobial susceptibility of Burkholderia pseudomallei. Materials & methods: The minimum inhibit...
- 7 February 2023
- Published by Taylor & Francis in Biofouling
- Vol. 39 (2) , 189-203
Effect of promethazine on biofilms of gram-positive cocci associated with infectious endocarditis
This study evaluated the antimicrobial activity of promethazine against Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus mutans and its effect on the antimicrobial susceptibility of biofilms grown in vitro and ex vivo on porcine heart valves. Promethazine was evaluated alone and in combination with vancomycin and oxacillin against Staphylococcus spp. and vancomycin and ceftriaxone against S. mutans in planktonic form and biofilms grown in vitro and ex vivo. Promethazine minimum inhibitory concentration range was 24.4-95.31 μg/mL and minimum biofilm eradication concentration range was 781.25-3.125 μg/mL. Promethazine interacted synergistically with vancomycin, oxacillin and ceftriaxone against biofilms in vitro. Promethazine alone reduced (p < 0.05) the CFU-counts of biofilms grown on heart valves for Staphylococcus spp., but not for S. mutans, and increased (p < 0.05) the activity of vancomycin, oxacillin and ceftriaxone against biofilms of Gram-positive cocci grown ex vivo. These findings bring perspectives for repurposing promethazine as adjuvant in the treatment of infective endocarditis.
- 7 February 2023
- Published by Taylor & Francis in Biofouling
- Vol. 39 (2) , 189-203
Effect of promethazine on biofilms of gram-positive cocci associated with infectious endocarditis
This study evaluated the antimicrobial activity of promethazine against Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus mutans and its effect on the antimicrobial susceptibility of biofilms grown in vitro and ex vivo on porcine heart valves. Promethazine was evaluated alone and in combination with vancomycin and oxacillin against Staphylococcus spp. and vancomycin and ceftriaxone against S. mutans in planktonic form and biofilms grown in vitro and ex vivo. Promethazine minimum inhibitory concentration range was 24.4-95.31 μg/mL and minimum biofilm eradication concentration range was 781.25-3.125 μg/mL. Promethazine interacted synergistically with vancomycin, oxacillin and ceftriaxone against biofilms in vitro. Promethazine alone reduced (p < 0.05) the CFU-counts of biofilms grown on heart valves for Staphylococcus spp., but not for S. mutans, and increased (p < 0.05) the activity of vancomycin, oxacillin and ceftriaxone against biofilms of Gram-positive cocci grown ex vivo. These findings bring perspectives for repurposing promethazine as adjuvant in the treatment of infective endocarditis.
- 7 February 2023
- Published by Taylor & Francis in Biofouling
- Vol. 39 (2) , 218-230
Promethazine inhibits efflux, enhances antifungal susceptibility and disrupts biofilm structure and functioning in Trichosporon
Trichosporon spp. are emerging opportunistic fungi associated with invasive infections, especially in patients with haematological malignancies. The present study investigated the in vitro inhibition of efflux pumps by promethazine (PMZ) as a strategy to control T. asahii and T. inkin. Planktonic cells were evaluated for antifungal susceptibility to PMZ, as well as inhibition of efflux. The effect of PMZ was also studied in Trichosporon biofilms. PMZ inhibited T. asahii and T. inkin planktonic cells at concentrations ranging from 32 to 256 μg ml–1. Subinhibitory concentrations of PMZ inhibited efflux activity in Trichosporon. Biofilms were completely eradicated by PMZ. PMZ potentiated the action of antifungals, affected the morphology, changed the amount of carbohydrates and proteins and reduced the amount of persister cells inside biofilms. The results showed indirect evidences of the occurrence of efflux pumps in Trichosporon and opens a perspective for the use of this target in the control of trichosporonosis.
- 7 February 2023
- Published by Taylor & Francis in Biofouling
- Vol. 39 (2) , 218-230
Promethazine inhibits efflux, enhances antifungal susceptibility and disrupts biofilm structure and functioning in Trichosporon
Trichosporon spp. are emerging opportunistic fungi associated with invasive infections, especially in patients with haematological malignancies. The present study investigated the in vitro inhibition of efflux pumps by promethazine (PMZ) as a strategy to control T. asahii and T. inkin. Planktonic cells were evaluated for antifungal susceptibility to PMZ, as well as inhibition of efflux. The effect of PMZ was also studied in Trichosporon biofilms. PMZ inhibited T. asahii and T. inkin planktonic cells at concentrations ranging from 32 to 256 μg ml–1. Subinhibitory concentrations of PMZ inhibited efflux activity in Trichosporon. Biofilms were completely eradicated by PMZ. PMZ potentiated the action of antifungals, affected the morphology, changed the amount of carbohydrates and proteins and reduced the amount of persister cells inside biofilms. The results showed indirect evidences of the occurrence of efflux pumps in Trichosporon and opens a perspective for the use of this target in the control of trichosporonosis.
- 7 February 2023
- Published by Taylor & Francis in Biofouling
- Vol. 39 (2) , 135-144
In vitro effect of the iron chelator deferiprone on the antimicrobial susceptibility and biofilms of Burkholderia pseudomallei
This study evaluated the effect of the iron chelator deferiprone (DFP) on antimicrobial susceptibility and biofilm formation and maintenance by Burkholderia pseudomallei. Planktonic susceptibility to DFP alone and in combination with antibiotics was evaluated by broth microdilution and biofilm metabolic activity was determined with resazurin. DFP minimum inhibitory concentration (MIC) range was 4–64 µg/mL and in combination reduced the MIC for amoxicillin/clavulanate and meropenem. DFP reduced the biomass of biofilms by 21 and 12% at MIC and MIC/2, respectively. As for mature biofilms, DFP reduced the biomass by 47%, 59%, 52% and 30% at 512, 256, 128 and 64 µg/mL, respectively, but did not affect B. pseudomallei biofilm viability nor increased biofilm susceptibility to amoxicillin/clavulanate, meropenem and doxycycline. DFP inhibits planktonic growth and potentiates the effect of β-lactams against B. pseudomallei in the planktonic state and reduces biofilm formation and the biomass of B. pseudomallei biofilms.
- 7 February 2023
- Published by Taylor & Francis in Biofouling
- Vol. 39 (2) , 135-144
In vitro effect of the iron chelator deferiprone on the antimicrobial susceptibility and biofilms of Burkholderia pseudomallei
This study evaluated the effect of the iron chelator deferiprone (DFP) on antimicrobial susceptibility and biofilm formation and maintenance by Burkholderia pseudomallei. Planktonic susceptibility to DFP alone and in combination with antibiotics was evaluated by broth microdilution and biofilm metabolic activity was determined with resazurin. DFP minimum inhibitory concentration (MIC) range was 4–64 µg/mL and in combination reduced the MIC for amoxicillin/clavulanate and meropenem. DFP reduced the biomass of biofilms by 21 and 12% at MIC and MIC/2, respectively. As for mature biofilms, DFP reduced the biomass by 47%, 59%, 52% and 30% at 512, 256, 128 and 64 µg/mL, respectively, but did not affect B. pseudomallei biofilm viability nor increased biofilm susceptibility to amoxicillin/clavulanate, meropenem and doxycycline. DFP inhibits planktonic growth and potentiates the effect of β-lactams against B. pseudomallei in the planktonic state and reduces biofilm formation and the biomass of B. pseudomallei biofilms.
- Open Access
- 5 November 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (11) , 1562
The Potential of Phenothiazines against Endodontic Pathogens: A Focus on Enterococcus-Candida Dual-Species Biofilm
Persistent apical periodontitis occurs when the endodontic treatment fails to eradicate the intraradicular infection, and is mainly caused by Gram-positive bacteria and yeasts, such as Enterococcus faecalis and Candida albicans, respectively. Phenothiazines have been described as potential antimicrobials against bacteria and fungi. This study aimed to investigate the antimicrobial potential of promethazine (PMZ) and chlorpromazine (CPZ) against E. faecalis and C. albicans dual-species biofilms. The susceptibility of planktonic cells to phenothiazines, chlorhexidine (CHX) and sodium hypochlorite (NaOCl) was initially analyzed by broth microdilution. Interaction between phenothiazines and CHX was examined by chequerboard assay. The effect of NaOCl, PMZ, CPZ, CHX, PMZ + CHX, and CPZ + CHX on biofilms was investigated by susceptibility assays, biochemical and morphological analyses. Results were evaluated through one-way ANOVA and Tukey’s multiple comparison post-test. PMZ, alone or in combination with irrigants, was the most efficient phenothiazine, capable of reducing cell counts, biomass, biovolume, carbohydrate and protein contents of dual-species biofilms. Neither PMZ nor CPZ increased the antimicrobial activity of CHX. Further investigations of the properties of phenothiazines should be performed to encourage their use in endodontic clinical practice.
- 5 November 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (11) , 1562
Open AccessThe Potential of Phenothiazines against Endodontic Pathogens: A Focus on Enterococcus-Candida Dual-Species Biofilm
Persistent apical periodontitis occurs when the endodontic treatment fails to eradicate the intraradicular infection, and is mainly caused by Gram-positive bacteria and yeasts, such as Enterococcus faecalis and Candida albicans, respectively. Phenothiazines have been described as potential antimicrobials against bacteria and fungi. This study aimed to investigate the antimicrobial potential of promethazine (PMZ) and chlorpromazine (CPZ) against E. faecalis and C. albicans dual-species biofilms. The susceptibility of planktonic cells to phenothiazines, chlorhexidine (CHX) and sodium hypochlorite (NaOCl) was initially analyzed by broth microdilution. Interaction between phenothiazines and CHX was examined by chequerboard assay. The effect of NaOCl, PMZ, CPZ, CHX, PMZ + CHX, and CPZ + CHX on biofilms was investigated by susceptibility assays, biochemical and morphological analyses. Results were evaluated through one-way ANOVA and Tukey’s multiple comparison post-test. PMZ, alone or in combination with irrigants, was the most efficient phenothiazine, capable of reducing cell counts, biomass, biovolume, carbohydrate and protein contents of dual-species biofilms. Neither PMZ nor CPZ increased the antimicrobial activity of CHX. Further investigations of the properties of phenothiazines should be performed to encourage their use in endodontic clinical practice.